Literature DB >> 15663474

Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment.

Naila Ahmed1, Usman Ahmed, Paul J Thornalley, Klaus Hager, Gerd Fleischer, Gerald Münch.   

Abstract

Increased damage to proteins by glycation, oxidation and nitration has been implicated in neuronal cell death leading to Alzheimer's disease (AD). Protein glycation, oxidation and nitration adducts are consequently formed. Quantitative screening of these adducts in CSF may provide a biochemical indicator for the diagnosis of AD. To assess this, we measured 11 glycation adducts, three oxidation adducts and a nitration adduct, determining both protein adduct residues and free adducts, in CSF samples of age-matched normal healthy subjects (n = 18) and subjects with Alzheimer's disease (n = 32). In CSF protein, the concentrations of 3-nitrotyrosine, N(epsilon)-carboxymethyl-lysine, 3-deoxyglucosone-derived hydroimidazolone and N-formylkynurenine residues were increased in subjects with Alzheimer's disease. In CSF ultrafiltrate, the concentrations of 3-nitrotyrosine, methylglyoxal-derived hydroimidazolone and glyoxal-derived hydroimidazolone free adducts were also increased. The Mini-Mental State Examination (MMSE) score correlated negatively with 3-nitrotyrosine residue concentration (p < 0.05), and the negative correlation with fructosyl-lysine residues just failed to reach significance (p = 0.052). Multiple linear regression gave a regression model of the MMSE score on 3-nitrotyrosine, fructosyl-lysine and N(epsilon)-carboxyethyl-lysine residues with p-values of 0.021, 0.031 and 0.052, respectively. These findings indicate that protein glycation, oxidation and nitration adduct residues and free adducts were increased in the CSF of subjects with Alzheimer's disease. A combination of nitration and glycation adduct estimates of CSF may provide an indicator for the diagnosis of Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15663474     DOI: 10.1111/j.1471-4159.2004.02864.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  60 in total

1.  Serum concentration of an inflammatory glycotoxin, methylglyoxal, is associated with increased cognitive decline in elderly individuals.

Authors:  Michal Schnaider Beeri; Erin Moshier; James Schmeidler; James Godbold; Jaime Uribarri; Sarah Reddy; Mary Sano; Hillel T Grossman; Weijing Cai; Helen Vlassara; Jeremy M Silverman
Journal:  Mech Ageing Dev       Date:  2011-11-03       Impact factor: 5.432

2.  Accumulation of methylglyoxal increases the advanced glycation end-product levels in DRG and contributes to lumbar disk herniation-induced persistent pain.

Authors:  Cui-Cui Liu; Xin-Sheng Zhang; Yu-Ting Ruan; Zhu-Xi Huang; Su-Bo Zhang; Meng Liu; Hai-Jie Luo; Shao-Ling Wu; Chao Ma
Journal:  J Neurophysiol       Date:  2017-06-14       Impact factor: 2.714

3.  Microbiota facilitates the formation of the aminated metabolite of green tea polyphenol (-)-epigallocatechin-3-gallate which trap deleterious reactive endogenous metabolites.

Authors:  Shuwei Zhang; Yantao Zhao; Christina Ohland; Christian Jobin; Shengmin Sang
Journal:  Free Radic Biol Med       Date:  2018-12-19       Impact factor: 7.376

Review 4.  The association of diabetes and dementia and possible implications for nondiabetic populations.

Authors:  Ramit Ravona-Springer; Michal Schnaider-Beeri
Journal:  Expert Rev Neurother       Date:  2011-11       Impact factor: 4.618

5.  Investigation Into the Effects of Tenilsetam on Markers of Neuroinflammation in GFAP-IL6 Mice.

Authors:  Erika Gyengesi; Huazheng Liang; Christopher Millington; Sandra Sonego; Daniel Sirijovski; Dhanushka Gunawardena; Karthik Dhananjayan; Madhuri Venigalla; Garry Niedermayer; Gerald Münch
Journal:  Pharm Res       Date:  2018-01-05       Impact factor: 4.200

6.  Oral glycotoxins are a modifiable cause of dementia and the metabolic syndrome in mice and humans.

Authors:  Weijing Cai; Jaime Uribarri; Li Zhu; Xue Chen; Shobha Swamy; Zhengshan Zhao; Fabrizio Grosjean; Calogera Simonaro; George A Kuchel; Michal Schnaider-Beeri; Mark Woodward; Gary E Striker; Helen Vlassara
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-24       Impact factor: 11.205

7.  Development of a neuroprotective potential algorithm for medicinal plants.

Authors:  Weixi Liu; Hang Ma; Nicholas A DaSilva; Kenneth N Rose; Shelby L Johnson; Lu Zhang; Chunpeng Wan; Joel A Dain; Navindra P Seeram
Journal:  Neurochem Int       Date:  2016-09-29       Impact factor: 3.921

8.  cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases.

Authors:  Philipp Spitzer; Hans Wolfgang Klafki; Kaj Blennow; Luc Buée; Hermann Esselmann; Sanna-Kaisa Herruka; Connie Jimenez; Peter Klivenyi; Piotr Lewczuk; Juan Manuel Maler; Katrin Markus; Helmut E Meyer; Chris Morris; Thorsten Müller; Markus Otto; Lucilla Parnetti; Hilkka Soininen; Susanna Schraen; Charlotte Teunissen; Laszlo Vecsei; Henrik Zetterberg; Jens Wiltfang
Journal:  Int J Alzheimers Dis       Date:  2010-09-19

9.  The S100B/RAGE Axis in Alzheimer's Disease.

Authors:  Estelle Leclerc; Emmanuel Sturchler; Stefan W Vetter
Journal:  Cardiovasc Psychiatry Neurol       Date:  2010-06-21

Review 10.  Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders.

Authors:  Yahya E Choonara; Viness Pillay; Lisa C Du Toit; Girish Modi; Dinesh Naidoo; Valence M K Ndesendo; Sibongile R Sibambo
Journal:  Int J Mol Sci       Date:  2009-06-03       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.